FDA Approves Datopotamab Deruxtecan-dlnk for Unresectable or Metastatic TNBC By Ogkologos - June 24, 2026 6 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the TROPION-Breast02 study Source RELATED ARTICLESMORE FROM AUTHOR High HPV Vaccination Coverage in England Associated with a Substantial Reduction in Cervical Cancer Mortality Oral Sunvozertinib Prolongs PFS Over Chemotherapy as First-Line Treatment for Patients with Advanced NSCLC with EGFR Exon 20 Insertions No Difference in DFS Between Post-adjuvant Chemotherapy and Placebo In High-Risk Patients Identified Through ctDNA-based MRD Assessment After CRC Resection MOST POPULAR EMA Recommends Granting a Marketing Authorisation for Capivasertib April 29, 2024 ΥΓΡΗ ΒΙΟΨΙΑ: ΤΟ ΜΕΛΛΟΝ ΣΤΗ ΔΙΑΓΝΩΣΗ ΤΟΥ ΚΑΡΚΙΝΟΥ November 26, 2018 EMA Recommends Granting a Conditional Marketing Authorisation for Selpercatinib December 16, 2020 Imiquimod is a Safe and Effective Alternative to Surgery for Vulvar... May 5, 2022 Load more HOT NEWS New Research in Treating Leukemia and Lymphoma: ASH Annual Meeting 2020 Holiday Coping and Enjoying Take with Food: Study Tests Lowering Dose of Prostate Cancer Drug Why Cancer Survivors Should Have a Written Survivorship Care Plan
